Fractyl reported six-month data on October 16, 2026 from the REMAIN-1 pivotal cohort of 308 adults who first lost at least 15% of body weight on tirzepatide. Revita patients retained 80% of that loss versus 67% for sham, with a p-value of 0.0023. The …
The largest percentage fall belongs to the thinnest trade. Per the 10-Q, the NYSE began delisting proceedings on March 2, 2026, a Form 25 was filed on March 18 and the shares now trade over the counter, where a trailing Q is the market …
On October 16, 2026, Fractyl Health reported six-month REMAIN-1 data for 308 adults: mean weight regain of 5.1% for Revita against 8.2% for sham, a co-primary endpoint win with a p-value of 0.0023, per the company release. The shares fell 48% to USD 2.17 …
Stardust Power fell 17.33% to USD 0.0334 from an implied prior close of USD 0.0404, own arithmetic, on 49.26 million shares at relative volume of 0.18. Turnover was USD 1.65 million, 121% of the USD 1.36 million market capitalization, own arithmetic. Nasdaq notified the …
Trinseo quoted USD 0.0035 per published market data, down 65% on 8.82 thousand shares, a turnover of USD 30.87 and a market value of USD 127.96 thousand, own arithmetic. The Q suffix is the market convention for a company in a bankruptcy case, and …
WF Holding sold 12,000,000 shares or pre-funded warrants at USD 1.50 in a USD 18 million registered direct offering announced on October 14, 2026, each with a one-year warrant, per the company release. Published market data shows USD 0.1278, 91.5% below that price, which …
No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026. The open at USD 2.08 (own arithmetic) reflected a 3.48% gap, and the 51.44% gain from the open means most of the rise came after the first trade, own …
The catalyst label is a foreign issuer report: a 6-K dated October 16, 2026 citing a Nasdaq letter of October 14, 2026 that confirmed compliance with the USD 1.00 minimum bid rule, Listing Rule 5550(a)(2). The stock opened at USD 3.40 and fell to …
No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026. Per published market data, the October 15, 2026 close was USD 32.52, which makes the decline to USD 31.89 equal to 1.94%, own arithmetic, while the 2.63% in the …
No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026. The gap was 2.76% and the gain from the open 0.40%, so the move was set at the open. Implied prior close is USD 3.62 and implied average volume …